{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:41:59Z","timestamp":1792503719368,"version":"4.5.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100007028","name":"Leona M. and Harry B. Helmsley Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01DK132408"],"award-info":[{"award-number":["R01DK132408"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["T32DK007727"],"award-info":[{"award-number":["T32DK007727"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30DK078392"],"award-info":[{"award-number":["P30DK078392"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>With modest rates of endoscopic remission to anti-TNF biologics in children with moderate-to-severe Crohn\u2019s disease (CD), there is a critical need to develop noninvasive biomarkers associated with anti-TNF response. We performed a comprehensive proteomic evaluation to identify peripheral-blood candidate biomarkers for anti-TNF response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The ENvISION study enrolled patients (2-19\u2009years old) with CD prior to starting infliximab or adalimumab with outcomes prospectively monitored at Month 3 (M3) and Month 12 (M12). The SomaScan\u00ae (Somalogic, Boulder, CO, 7322 analytes) was performed prior to anti-TNF treatment (baseline) at M3 and M12. Endoscopic remission was assessed at M12 (simple endoscopic score-CD &amp;lt; 3).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighty patients with CD were enrolled with the CD Core Proteome developed from 61 prednisone-naive CD and 30 healthy controls. We identified 2999 differentially abundant proteins, 1403 with lower abundance and 1596 with higher abundance (FDR &amp;lt; 0.05). The CD Core Proteome was then compared across the three timepoints (baseline, M3 and M12) and we found that at both M3 and M12, the Core Proteome dysregulation retains strong identity with the baseline protein signal (\u03b2\u2009=\u2009.7, P &amp;lt; .001; \u03b2\u2009=\u2009.63, P &amp;lt; .001, respectively). Although the proteome exhibits change over time, it does not revert to a control-like state; rather, it transitions to a distinct \u201ctreated CD\u201d proteome. In an exploratory investigation of the change in (delta) protein abundance from baseline to M3, we identified 132 proteins nominally associated with M12 endoscopic remission (P &amp;lt; .01). Using elastic net regression, we identified a three-protein panel (IRF1, NEUROG1, and APOA5) associated with M12 endoscopic remission (AUROC 0.94, 95% CI 0.88-1.0).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In an exploratory investigation, we identified a CD Core Proteome and three-protein panel whose early changes were associated with M12 endoscopic remission, supporting their use as early pharmacodynamic response markers following external validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag221","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:10:25Z","timestamp":1792501825000},"source":"Crossref","is-referenced-by-count":0,"title":["Large-scale proteomics identifies a pretreatment Crohn\u2019s disease core proteome and a dynamic signature for anti-TNF response"],"prefix":"10.1093","author":[{"given":"Rebekah","family":"Karns","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S","family":"Hyams","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Connecticut Children\u2019s Medical Center , Hartford, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan M","family":"Boyle","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nationwide Children\u2019s Hospital , Columbus, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D","family":"Noe","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Medical College of Wisconsin , Milwaukee, WI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Jackson","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Lynch","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Kate","family":"Ewalt","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Nasr","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH,","place":["United States"]},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine , Cincinnati, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Aviles","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee A","family":"Denson","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH,","place":["United States"]},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine , Cincinnati, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4223-4211","authenticated-orcid":false,"given":"Phillip","family":"Minar","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH,","place":["United States"]},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine , Cincinnati, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"2026102009102219000_izag221-B1","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/MIB.0000000000001021","article-title":"Long-term efficacy and safety of adalimumab in pediatric patients with Crohn\u2019s disease","volume":"23","author":"Faubion","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2026102009102219000_izag221-B2","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.crohns.2012.01.019","article-title":"Restoration of quality of life of patients with inflammatory bowel disease after one year with antiTNF\u03b1 treatment","volume":"6","author":"Casellas","year":"2012","journal-title":"J Crohns Colitis"},{"key":"2026102009102219000_izag221-B3","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/S0140-6736(17)30317-3","article-title":"Prediction of complicated disease course for children newly diagnosed with Crohn\u2019s disease: a multicentre inception cohort study","volume":"389","author":"Kugathasan","year":"2017","journal-title":"Lancet"},{"key":"2026102009102219000_izag221-B4","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1093\/ibd\/izaa102","article-title":"Effect of a practice-wide anti-TNF proactive therapeutic drug monitoring program on outcomes in pediatric patients with inflammatory bowel disease","volume":"27","author":"Lyles","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026102009102219000_izag221-B5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/MPG.0000000000002832","article-title":"Therapeutic drug monitoring-guided high-dose infliximab for infantile-onset inflammatory bowel disease: a case series","volume":"71","author":"Assa","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026102009102219000_izag221-B6","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1097\/MPG.0000000000002262","article-title":"Predictors of long-term clinical and endoscopic remission in children with Crohn disease treated with infliximab","volume":"68","author":"D\u2019Arcangelo","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026102009102219000_izag221-B7","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.cgh.2024.01.026","article-title":"Biomarkers for personalizing IBD therapy: the quest continues","volume":"22","author":"Atreya","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026102009102219000_izag221-B8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026102009102219000_izag221-B9","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1172\/JCI75436","article-title":"Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature","volume":"124","author":"Haberman","year":"2014","journal-title":"J Clin Invest"},{"key":"2026102009102219000_izag221-B10","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1002\/ibd.21301","article-title":"Predictive value of epithelial gene expression profiles for response to infliximab in Crohn\u2019s disease","volume":"16","author":"Arijs","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"2026102009102219000_izag221-B11","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.cell.2019.08.008","article-title":"Single-cell analysis of Crohn\u2019s disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy","volume":"178","author":"Martin","year":"2019","journal-title":"Cell"},{"key":"2026102009102219000_izag221-B12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2020.03.007","article-title":"Serum biomarkers identify patients who will develop inflammatory bowel diseases up to 5 years before diagnosis","volume":"159","author":"Torres","year":"2020","journal-title":"Gastroenterology"},{"key":"2026102009102219000_izag221-B13","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1038\/ctg.2016.49","article-title":"Identification of pathway-specific serum biomarkers of response to glucocorticoid and infliximab treatment in children with inflammatory bowel disease","volume":"7","author":"Heier","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"2026102009102219000_izag221-B14","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1097\/MPG.0000000000003030","article-title":"Diagnostic accuracy of the Rome IV criteria for the diagnosis of functional gastrointestinal disorders in children","volume":"72","author":"Velasco-Benitez","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026102009102219000_izag221-B15","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/ajg.2009.545","article-title":"Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn\u2019s disease (SES-CD) than CRP, blood leukocytes, and the CDAI","volume":"105","author":"Schoepfer","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2026102009102219000_izag221-B16","doi-asserted-by":"publisher","first-page":"14248","DOI":"10.1038\/s41598-017-14755-5","article-title":"Assessment of variability in the SOMAscan assay","volume":"7","author":"Candia","year":"2017","journal-title":"Sci Rep"},{"key":"2026102009102219000_izag221-B17","doi-asserted-by":"publisher","first-page":"S-226","DOI":"10.1016\/S0016-5085(24)01007-2","article-title":"Attaining early anti-TNF exposure targets is associated with improved rates of endoscoic healing and transmural healing in children with Crohn\u2019s disease","volume":"166","author":"Nasr","year":"2024","journal-title":"Gastroenterology"},{"key":"2026102009102219000_izag221-B18","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res"},{"key":"2026102009102219000_izag221-B19","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1097\/MIB.0000000000000043","article-title":"Mechanisms that mediate the development of fibrosis in patients with Crohn\u2019s disease","volume":"20","author":"Li","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2026102009102219000_izag221-B20","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.3390\/biomedicines13071777","article-title":"Insights into the molecular mechanisms and novel therapeutic strategies of stenosis fibrosis in Crohn\u2019s disease","volume":"13","author":"Zhou","year":"2025","journal-title":"Biomedicines"},{"key":"2026102009102219000_izag221-B21","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/ibd\/izab038","article-title":"The pathogenesis and clinical management of stricturing Crohn disease","volume":"27","author":"Schmoyer","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026102009102219000_izag221-B22","doi-asserted-by":"publisher","first-page":"107350","DOI":"10.1016\/j.intimp.2020.107350","article-title":"IRF\/Type I IFN signaling serves as a valuable therapeutic target in the pathogenesis of inflammatory bowel disease","volume":"92","author":"Li","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"2026102009102219000_izag221-B23","doi-asserted-by":"publisher","first-page":"8362","DOI":"10.1038\/s41467-023-43602-7","article-title":"Essential transcription factors for induced neuron differentiation","volume":"14","author":"Lu","year":"2023","journal-title":"Nat Commun"},{"key":"2026102009102219000_izag221-B24","doi-asserted-by":"publisher","first-page":"8052954","DOI":"10.1155\/2020\/8052954","article-title":"Apolipoprotein A-V is a novel diagnostic and prognostic predictor in pediatric patients with sepsis: a prospective pilot study in PICU","volume":"2020","author":"Wang","year":"2020","journal-title":"Mediators Inflamm"},{"key":"2026102009102219000_izag221-B25","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/ecco-jcc\/jjad049","article-title":"Serum immune profiling in paediatric Crohn\u2019s disease demonstrates stronger immune modulation with first-line infliximab than conventional therapy and pre-treatment profiles predict clinical response to both treatments","volume":"17","author":"Jongsma","year":"2023","journal-title":"J Crohns Colitis"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag221\/72132759\/izag221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag221\/72132759\/izag221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:10:27Z","timestamp":1792501827000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article\/doi\/10.1093\/ibd\/izag221\/8944036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":25,"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag221","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"article-number":"izag221"}}